Ceramide (18:0)
lipidCeramide (18:0) accumulates in atherosclerotic lesions and predicts adverse cardiovascular outcomes through altered lipid metabolism and plaque destabilization.
Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleCeramide accumulation in atherosclerotic plaques; sphingolipid dysregulation in CAD.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only
Literature evidence(1)
- Plasma Ceramides.Arteriosclerosis, thrombosis, and vascular biology · 2018 · PMID 29903731 · doi